Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

4.005 +0.015 (+0.38%)
Streaming Delayed Price Updated: 1:51 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Geron Corp

< Previous 1 2 3 4 5 Next >
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Geron Corp. (NASDAQ: GERN) Near Top of Volume Charts in Friday Trading
Via Investor Brand Network
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
From Geron
Via Business Wire
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
From Geron Corporation
Via Business Wire
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation: FDA Approval Fuels Stock Price Surge
FDA approval paves the way for Geron Corporation's rise as a leader in hematologic malignancy treatments. 
Via MarketBeat
Exposures Product Safety
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Geron Corporation
Via Business Wire
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback